Characterization of NEB pathogenic variants in patients reveals novel nemaline myopathy disease mechanisms and omecamtiv mecarbil force effects
Acta Neuropathologica · 2024
DOI: 10.1007/s00401-024-02726-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Neuropathologica, 2024. Verfasst von Esmat Karimi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ, USA. Hauptthemen laut MEDLINE: Myopathies, Nemaline, Urea. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, Institute of Musculoskeletal Health and Arthritis.
Abstract (Originalsprache)
Nebulin, a critical protein of the skeletal muscle thin filament, plays important roles in physiological processes such as regulating thin filament length (TFL), cross-bridge cycling, and myofibril alignment. Pathogenic variants in the nebulin gene ( NEB ) cause NEB-based nemaline myopathy (NEM2), a genetically heterogeneous disorder characterized by hypotonia and muscle weakness, currently lacking curative therapies. In this study, we examined a cohort of ten NEM2 patients, each with unique pathogenic variants, aiming to understand their impact on mRNA, protein, and functional levels. Results show that pathogenic truncation variants affect NEB mRNA stability and lead to nonsense-mediated decay of the mutated transcript. Moreover, a high incidence of cryptic splice site activation was found in patients with pathogenic splicing variants that are expected to disrupt the actin-binding sites of nebulin. Determination of protein levels revealed patients with either relatively normal or markedly reduced nebulin. We observed a positive relation between the reduction in nebulin and a reduction in TFL, or reduction in tension (both maximal and submaximal tension). Interestingly, our study revealed a pathogenic duplication variant in nebulin that resulted in a four-copy gain in the triplicate region of NEB and a much larger nebulin protein and longer TFL. Additionally, we investigated the effect of Omecamtiv mecarbil (OM), a small-molecule activator of cardiac myosin, on force production of type 1 muscle fibers of NEM2 patients. OM treatment substantially increased submaximal tension across all NEM2 patients ranging from 87 to 318%, with the largest effects in patients with the lowest level of nebulin. In summary, this study indicates that post-transcriptional or post-translational mechanisms regulate nebulin expression. Moreover, we propose that the pathomechanism of NEM2 involves not only shortened but also elongated thin filaments, along with the disruption of actin-binding sites resulting from pathogenic splicing variants. Significantly, our findings highlight the potential of OM treatment to improve skeletal muscle function in NEM2 patients, especially those with large reductions in nebulin levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ, USA.
- Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA.
- Diverge Translational Science Laboratory, Milwaukee, WI, USA.
- Department of Physiology, Amsterdam UMC (Location VUMC), Amsterdam, Netherlands.
- Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ, USA. granzier@arizona.edu.
ORCID-Profile: Henk Granzier
Förderung
- NIAMS NIH HHS
- Institute of Musculoskeletal Health and Arthritis
Zitieren
APA
Karimi, E., Gohlke, J., van der Borgh, M., Lindqvist, J., Hourani, Z., Kolb, J., Cossette, S., Lawlor, M. W., Ottenheijm, C., & Granzier, H. (2024). Characterization of NEB pathogenic variants in patients reveals novel nemaline myopathy disease mechanisms and omecamtiv mecarbil force effects. Acta Neuropathologica. https://doi.org/10.1007/s00401-024-02726-w
Vancouver
Karimi E, Gohlke J, van der Borgh M, Lindqvist J, Hourani Z, Kolb J, et al. Characterization of NEB pathogenic variants in patients reveals novel nemaline myopathy disease mechanisms and omecamtiv mecarbil force effects. Acta Neuropathologica. 2024. doi:10.1007/s00401-024-02726-w
BibTeX
@article{Karimi2024,
author = {Karimi, Esmat and Gohlke, Jochen and van der Borgh, Mila and Lindqvist, Johan and Hourani, Zaynab and Kolb, Justin and Cossette, Stacy and Lawlor, Michael W and Ottenheijm, Coen and Granzier, Henk},
title = {Characterization of NEB pathogenic variants in patients reveals novel nemaline myopathy disease mechanisms and omecamtiv mecarbil force effects},
journal = {Acta Neuropathologica},
year = {2024},
doi = {10.1007/s00401-024-02726-w}
}
EUVIMED